share_log

Shuttle Pharma Pays Off Senior Secured Convertible Note

Shuttle Pharma Pays Off Senior Secured Convertible Note

Shuttle Pharma支付了高級擔保可轉換票據
GlobeNewswire ·  10/30 04:05

GAITHERSBURG, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that, during the third quarter of this year, it paid off the entirety of the outstanding balance due under its Senior Secured Convertible Note ("Note") issued on January 11, 2023.

馬里蘭蓋瑟斯堡,2024年10月29日(全球新聞社)—Shuttle Pharmaceuticals Holdings, Inc.(納斯達克:SHPH)(「Shuttle Pharma」)是一家專注於改善接受放射治療(RT)的癌症患者預後的發現和開發階段的專業藥品公司。今天宣佈,今年第三季度,它償還了於2023年1月11日發行的優先擔保可轉換票據(「票據」)的全部未償餘額。

The initial balance of the Note was $4.3 million and was originally repayable over a 26-month period ending March 11, 2025. During the term of the note, Shuttle Pharma made periodic cash payments totaling $1.3 million and equity issuances totaling 1,094,970 shares (on a post reverse split basis). As a result, the Company now has a total of 2,946,099 shares outstanding. Additionally, in October 2024, Shuttle Pharma closed on a convertible note and warrant offering, receiving a total of $790,000 in gross proceeds, including $237,500 invested by the Company's Chief Executive Officer, Dr. Anatoly Dritschilo.

票據的初始餘額爲430萬美元,最初應在26個月期限內償還,截至2025年3月11日結束。在票據期間,Shuttle Pharma進行了總計130萬美元的定期現金支付和總計1,094,970股的股本發行(以發帖反向拆分爲基礎)。因此,公司現在擁有總計2,946,099股的流通股。此外,2024年10月,Shuttle Pharma完成了可轉換票據和認股權證發行,獲得了總額爲79萬美元的總收入,其中包括公司首席執行官安納託利·德里奇洛博士投資的23.75萬美元。

"The elimination of the convertible note along with obtaining the bridge funding provides us with added flexibility to advance our ongoing Phase 2 clinical trial for the treatment of patients with glioblastoma," commented Shuttle Pharma's Chairman and CEO, Anatoly Dritschilo, M.D. "Over the past few months, Shuttle Pharma has made progress on a number of key activities. Along with our paydown of the convertible note and raising interim bridge funding, we have entered into agreements with six trial sites, five of which are now fully prepared to begin treating patients in the Phase 2 clinical trial. I look forward to maintaining our focus towards achieving our goal of increasing cancer cure rates, prolonging patient survival, and improving the quality of life for patients suffering from glioblastoma."

「消除可轉換票據並獲得過橋融資爲我們提供了額外靈活性,以推進我們正在進行的治療腦膠質母細胞瘤(glioblastoma)患者的2期臨床試驗,」Shuttle Pharma的主席兼首席執行官安納託利·德里奇洛萬.D.. 「在過去幾個月裏,Shuttle Pharma在許多關鍵活動上取得了進展。除了償還可轉換票據和籌集過橋資金,我們還與六個試驗地點達成協議,其中五個目前已完全準備好開始治療2期臨床試驗的患者。我期待着繼續專注於實現提高癌症治癒率、延長患者生存時間並改善患有腦膠質母細胞瘤的患者生活質量的目標。」

The Phase 2 clinical trial has begun enrolling patients with the most aggressive brain tumors out there – IDH wild-type, methylation negative glioblastoma. Presently, radiation is the only approved standard of care for this particular group of patients, with more than half of the patients surviving for less than 12 months after diagnosis. Shuttle Pharma's Phase 2 clinical trial will consist initially of 40 patients randomized into two different doses (20 @ 1,200 mg/day and 20 @ 960 mg/day) to determine an optimal dose. Once the Company determines the optimal dose, it will then add an additional 14 patients on the optimal dosage allowing for the achievement of statistical significance with the end point being that of survival as compared to historical controls. The Company expects the trial to be completed over a period of 18 to 24 months.

2期臨床試驗已經開始招募最具侵略性的腦瘤患者——IDH野生型、甲基化陰性的腦膠質母細胞瘤。目前,放射療法是這一特定患者群體唯一獲批准的標準治療方法,超過一半的患者在診斷後存活不足12個月。Shuttle Pharma的2期臨床試驗最初將包括40名患者,隨機分爲兩個不同劑量組(20 @ 1,200毫克/天和20 @ 960毫克/天)以確定最佳劑量。一旦公司確定了最佳劑量,它將再增加14名患者參與最佳劑量允許的成果的統計顯著性,終點爲存活與歷史對照相比。公司預計試驗將在18至24個月內完成。

An estimated 800,000 patients in the US are treated with radiation therapy for their cancers yearly. According to the American Cancer Society and the American Society of Radiation Oncologists, about 50% are treated for curative purposes and the balance for therapeutic care. The market opportunity for radiation sensitizers lies with the 400,000 patients treated for curative purposes, with this number expected to grow by more than 22% over the next five years.

據美國癌症協會和美國放射腫瘤學會稱,每年大約有估計80萬名美國患者接受放射治療。其中約50%接受治療以獲得治癒效果,其餘的接受治療以獲得治療護理。放射增敏劑的市場機會在於40萬名接受治療以獲得治癒效果的患者身上,預計未來五年這一數字將增長超過22%。

More information about the Phase 2 study (NCT06359379) can be found at .

有關第2期研究(NCT06359379)的更多信息,請訪問。

About Shuttle Pharmaceuticals

關於Shuttle藥品

Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at .

Shuttle Pharma成立於2012年,由喬治敦大學醫學中心的教師們共同創辦,是一家專注於發現和開發治療放療(RT)癌症患者的藥物的公司。我們的使命是通過開發放射線增敏劑來提高放療的效果,同時限制放射線在癌症治療中的副作用,從而改善癌症患者的生活質量。雖然放療是治療癌症的一種經過驗證的療法,但通過開發放射線增敏劑,我們旨在在作爲主要治療或與手術、化療和免疫療法聯合使用時,增加癌症治癒率,延長患者生存期並提高生活質量。有關更多信息,請訪問我們的網站:.

Safe Harbor Statement

Safe Harbor聲明

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements concerning the development of our company. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the "Risk Factors" section of Shuttle Pharma's Annual Report on Form 10-K for the year ended December 31, 2023, as amended, filed with the SEC on September 4, 2024, as well as other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharmaceuticals specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

本新聞稿中關於未來預期、計劃和前景的聲明,以及有關不屬於歷史事實的事項的任何其他聲明,可能構成"前瞻性聲明"。這些聲明包括但不限於有關我們公司發展的聲明。"預期"、"相信"、"繼續"、"可能"、"估計"、"期望"、"打算"、"可能"、"計劃"、"潛在"、"預測"、"項目"、"應該"、"目標"、"將"、"將會"以及類似表述,旨在識別前瞻性聲明,儘管並非所有前瞻性聲明都包含這些識別詞彙。實際結果可能會因各種重要因素而與此類前瞻性聲明所指示的結果存在實質性差異, 包括Shuttle Pharma於2023年12月31日年度報告中討論的因素,在2024年9月4日向SEC提交的10-k表格中,以及其他SEC提交文件中討論的因素。本新聞稿中包含的任何前瞻性聲明僅於本日期作出,Shuttle Pharmaceuticals除遵守聯邦證券法的要求外,特別聲明不會更新任何前瞻性聲明,無論是因新信息、未來事件還是其他原因。

Shuttle Pharmaceuticals
Anatoly Dritschilo, M.D., CEO
240-403-4212
info@shuttlepharma.com

Shuttle Pharmaceuticals
Anatoly Dritschilo萬.D.,首席執行官
240-403-4212
info@shuttlepharma.com

Investor Contacts
Lytham Partners, LLC
Robert Blum
602-889-9700
shph@lythampartners.com

投資者聯繫方式
Lytham Partners, LLC
Robert Blum
602-889-9700
shph@lythampartners.com


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論